Evidence & regulatory context
- Mechanism
- Cell therapy engineered to overexpress miR-124; no ChEMBL small-molecule entity. ClinicalTrials.gov returned no trial of miR-124-transfected neural stem cells (unmodified NSC trials exist but were not attributed here).
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- NSC; miR-124; microRNA-124
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryUnspecifiedWistarIntravenous injectionAfter spinal cord injury (acute phase; exact interval not stated)
Model: Experimental spinal cord injury in rats (model details not specified in the abstract)
Intravenous delivery of miR-124-transfected neural stem cells increased neuronal differentiation, reduced astrocytic differentiation, reduced lesion cavity volume and produced better functional recovery than untransfected neural stem cells or sham controls.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
